Bradykinin-mediated angioedema

Area of Science:

• Immunology
• Dermatology
• Allergy and Clinical Immunology

Background:

• Angioedema and urticaria are common clinical challenges with complex, multifactorial pathomechanisms.
• These conditions can co-occur or present independently, necessitating tailored treatment strategies.
• Understanding the underlying mechanisms, allergic or non-allergic, is crucial for effective management.

Purpose of the Study:

• To differentiate between allergic and non-allergic angioedema and urticaria.
• To highlight the distinct pathomechanisms, including histamine- and bradykinin-mediated pathways.
• To review current and emerging therapeutic approaches for these conditions.

Main Methods:

• Review of existing literature on angioedema and urticaria.
• Classification of angioedema types, including hereditary (HAE), acquired (AAE), and drug-induced forms.
• Analysis of treatment strategies, focusing on C1 inhibitor (C1-INH) concentrates and novel bradykinin pathway inhibitors.

Main Results:

• Distinguished between IgE-mediated, non-IgE-mediated allergic, and non-allergic angioedema.
• Identified 5 types of non-allergic angioedema: HAE, AAE, renin-angiotensin-aldosterone system-induced, pseudoallergic, and idiopathic.
• Bradykinin-mediated angioedema, particularly laryngeal, poses life-threatening risks due to resistance to standard treatments.
• C1-INH concentrates are primary treatments for HAE and AAE.
• New drugs like icatibant and ecallantide show promise for bradykinin-mediated angioedema.

Conclusions:

• Effective management of angioedema and urticaria requires understanding their diverse etiologies and pathomechanisms.
• Bradykinin-mediated angioedema necessitates specific treatments beyond corticosteroids and antihistamines.
• Emerging therapies targeting the bradykinin pathway significantly improve treatment outcomes for severe angioedema.